Pulmonary arterial hypertension (PAH) is a costly disease, both financially and personally. Survival rates have improved with targeted therapies, but could probably be improved more with aggressive management of medications to achieve low-risk status. Management of these patients requires complex, expensive regimens, which are likely best managed by a multidisciplinary team in a pulmonary hypertension center.
|Number of pages||6|
|Journal||Journal of Managed Care Medicine|
|State||Published - 2019|